- Vericel is a high growth, disruptive medical technology company with average 5-year sales growth of 24%.
- The Company’s tissue repair and restoration products are proprietary and backed by medical research showing greater effectiveness than traditional competing solutions/approaches.
- Significant growth opportunities remain for the company in both the sports medicine and severe burn treatment segments.
- Today’s valuation provides a compelling entry point for investors with a 3+ year time horizon.
For further details see:
Vericel - A Disruptive Business With Years Of Growth Remaining